Cargando…

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice

INTRODUCTION: The aim of this study is to evaluate adherence and persistence of patients treated with Imatinib, Nilotinib or Dasatinib, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS: In this retrospective study, we took into account 3 years fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoleri, Fiorenzo, Sorice, Paola, Lasala, Ruggero, Rizzo, Rosa Carmela, Costantini, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577678/ https://www.ncbi.nlm.nih.gov/pubmed/23437249 http://dx.doi.org/10.1371/journal.pone.0056813

Ejemplares similares

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
por: Zeng, Jing, et al.
Publicado: (2017)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
por: Mealing, Stuart, et al.
Publicado: (2013)

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy
por: Woywod, Clemens, et al.
Publicado: (2017)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
por: Dessilly, Géraldine, et al.
Publicado: (2016)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Dasatinib/imatinib: Treatment failure: case report
Publicado: (2022)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Effects of imatinib and nilotinib on the whole transcriptome of cultured murine osteoblasts
por: Kirschner, Gyöngyi, et al.
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
por: Inoue, Hiroyasu, et al.
Publicado: (2020)

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network
por: Nunes, Rafael Amorim Belo, et al.
Publicado: (2023)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Nilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo
por: Wei, Jiang, et al.
Publicado: (2014)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection
por: Yokoyama, Yuta, et al.
Publicado: (2022)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
por: Hughes, T P, et al.
Publicado: (2017)

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
por: Sánchez-Ortega, Isabel, et al.
Publicado: (2016)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

Évolution de leucémies myéloïdes chroniques sous nilotinib après échec a l'imatinib
por: Sawadogo, Salifo, et al.
Publicado: (2014)

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
por: Ananthula, Hari Krishna, et al.
Publicado: (2018)

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics
por: Alhazzani, Khalid, et al.
Publicado: (2023)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
por: Breccia, Massimo, et al.
Publicado: (2008)

Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib
por: Pantazi, Despoina, et al.
Publicado: (2019)

Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis
por: Adel, Ahmad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_te2emsvmhvinn10ktpehaddf5l